Jill Brown Cholangiocarcinoma | Podcast on losing her daughter Catie
Listen to the Jill Brown cholangiocarcinoma podcast as she shares losing her daughter Catie at 22 and reflects on grief and resilience.
Bridging Funding Australia Why Approved Medicines Take 466 Days to Reach Patients
Australia approves medicines that patients cannot access for an average of 466 days. This article explains why the delay exists, what bridging funding is, and why it matters to patients and caregivers.
ATM Mutation in Cancer: Context Before Conclusions
If ATM has appeared in your genetic or tumour reports, this article explains what ATM mutation in cancer really means, how it relates to MMR and BRCA1/2, and why biological context matters far more than the gene name alone.
Lisa Craine – Cholangiocarcinoma Patient
Lisa Craine -Cholangiocarcinoma patient. Lisa speaks at the 2017 CCF [...]
HER2 Biliary Cancer: ERBB2 & Enhertu Explained
Learn how ERBB2 mutations lead to HER2 overexpression, why it appears more in distal bile ducts and gallbladder cancers, and how Enhertu targets it with precision.
Cholangiocarcinoma Australia Webinar Review 2025
Full review of the Cholangiocarcinoma Foundation Australia’s 2025 webinar. Key insights on genomic profiling, treatment gaps, and steps to national care standards.
Jill Brown Cholangiocarcinoma | Podcast on losing her daughter Catie
Listen to the Jill Brown cholangiocarcinoma podcast as she shares losing her daughter Catie at 22 and reflects on grief and resilience.
Bridging Funding Australia Why Approved Medicines Take 466 Days to Reach Patients
Australia approves medicines that patients cannot access for an average of 466 days. This article explains why the delay exists, what bridging funding is, and why it matters to patients and caregivers.
ATM Mutation in Cancer: Context Before Conclusions
If ATM has appeared in your genetic or tumour reports, this article explains what ATM mutation in cancer really means, how it relates to MMR and BRCA1/2, and why biological context matters far more than the gene name alone.
Lisa Craine – Cholangiocarcinoma Patient
Lisa Craine -Cholangiocarcinoma patient. Lisa speaks at the 2017 CCF [...]
HER2 Biliary Cancer: ERBB2 & Enhertu Explained
Learn how ERBB2 mutations lead to HER2 overexpression, why it appears more in distal bile ducts and gallbladder cancers, and how Enhertu targets it with precision.
Cholangiocarcinoma Australia Webinar Review 2025
Full review of the Cholangiocarcinoma Foundation Australia’s 2025 webinar. Key insights on genomic profiling, treatment gaps, and steps to national care standards.
